Circio Enters Research Collaboration With Solid Biosciences To Evaluate Combining CircVec Generation 5 Construct With POLARIS-101 AAV Capsid For Genetic Heart Disease Gene Therapy
Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
William Blair Assumes Solid Biosciences at Outperform
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
Solid Biosciences Says European Commission Grants Orphan Designation To SGT-212 For Treatment Of Friedreich’s Ataxia
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations
RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $25 Price Target
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Solid Biosciences to Participate at Upcoming Investor Conferences
Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26
Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
Solid Biosciences Q2 EPS $(0.38) Beats $(0.46) Estimate
Solid Biosciences Files Prospectus To Offer Up To $200M In Common Stock
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.